drugset / Trial / NCT03921268

Study to Assess Effect of Device and Formulation on Pharmacokinetics (PK) of AZD1402

NCT03921268

Phase 1 Completed 18 enrolled AstraZeneca
RandomizedCrossoverOpen-labelTreatment

Summary

To evaluate and compare the pharmacokinetics profiles of AZD1402 after oral inhalation as an inhalation powder and a nebuliser solution. To further assess the safety and tolerability of single doses of AZD1402 in healthy volunteers. To evaluate the taste characteristics of the test formulations.

Timeline

Start
2019-03-25
Primary completion
2019-06-13
Completion
2019-06-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Elarekibep Protein / enzyme biologic Inhaled

Indications